{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:27:20Z","timestamp":1793662040480,"version":"4.5.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gebro Pharma"},{"name":"MSD"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers"},{"name":"Janssen"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clementia"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ajo.2018.12.019","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T12:12:48Z","timestamp":1547727168000},"page":"85-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"special_numbering":"C","title":["Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients"],"prefix":"10.1016","volume":"200","author":[{"given":"Nuria","family":"Vegas-Revenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Calvo-R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mesquida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Valls Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u00edaz-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"D\u00edaz-Cordov\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Hernandez-Garfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Mart\u00ednez-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Atanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gonz\u00e1lez-Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Demetrio-Pablo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Aurrecoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda C.","family":"Dom\u00ednguez-Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Atienza-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Mart\u00edn-Varillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Loricera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Palmou-Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajo.2018.12.019_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000081203","article-title":"Pathomechanisms of cystoid macular edema","volume":"36","author":"Bringmann","year":"2004","journal-title":"Ophthalmic Res"},{"issue":"6","key":"10.1016\/j.ajo.2018.12.019_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/ICU.0b013e3282f03d2e","article-title":"Inflammatory cystoid macular edema","volume":"18","author":"Rothova","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2018.12.019_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjo.80.9.844","article-title":"The possible impact of uveitis in blindness: a literature survey","volume":"80","author":"Suttorp-Schulten","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2018.12.019_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2018.12.019_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000320077","article-title":"Cystoid macular edema in uveitis","volume":"47","author":"de Smet","year":"2010","journal-title":"Dev Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2018.12.019_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","article-title":"Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients","volume":"45","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ajo.2018.12.019_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/08820530500231938","article-title":"Sarcoidosis","volume":"20","author":"Bonfioli","year":"2005","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2018.12.019_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.revmed.2010.09.003","article-title":"[Sarcoid uveitis: Diagnostic and therapeutic update]","volume":"32","author":"Varron","year":"2011","journal-title":"Rev Med Interne"},{"issue":"3","key":"10.1016\/j.ajo.2018.12.019_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti\u2013interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis\u2013associated uveitis refractory to anti\u2013tumor necrosis factor therapy: a multicenter study of twenty-five patients","volume":"69","author":"Calvo-R\u00edo","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ajo.2018.12.019_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12969-015-0018-8","article-title":"Characteristics of a cohort of children with juvenile idiopathic arthritis and JIA-associated uveitis","volume":"13","author":"Angeles-Han","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"10.1016\/j.ajo.2018.12.019_bib11","first-page":"2446","article-title":"Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis","volume":"29","author":"Zulian","year":"2002","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ajo.2018.12.019_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","article-title":"A case of Beh\u00e7et\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.ajo.2018.12.019_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/jovr.jovr_254_15","article-title":"Characteristics of macular edema in Behcet disease after intravitreal bevacizumab injection","volume":"12","author":"Ghassemi","year":"2017","journal-title":"J Ophthalmic Vis Res"},{"issue":"11","key":"10.1016\/j.ajo.2018.12.019_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/eye.2016.133","article-title":"Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis","volume":"30","author":"Grajewski","year":"2016","journal-title":"Eye Lond"},{"issue":"11","key":"10.1016\/j.ajo.2018.12.019_bib15","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","article-title":"Tocilizumab treatment for refractory uveitis-related cystoid macular edema","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2018.12.019_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ophtha.2008.09.034","article-title":"Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion","volume":"116","author":"Noma","year":"2009","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2018.12.019_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pathophys.2017.05.005","article-title":"Interleukin-6 participation in pathology of ocular diseases","volume":"24","author":"Zahir-Jouzdani","year":"2017","journal-title":"Pathophysiology"},{"issue":"7","key":"10.1016\/j.ajo.2018.12.019_bib18","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","article-title":"IL-6 blockade in the management of non-infectious uveitis","volume":"36","author":"Lopalco","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2018.12.019_bib19","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1111\/aos.13015","article-title":"Outcome of tocilizumab treatment in refractory ocular inflammatory diseases","volume":"94","author":"Silpa-Archa","year":"2016","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"12","key":"10.1016\/j.ajo.2018.12.019_bib20","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","article-title":"Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema","volume":"121","author":"Mesquida","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2018.12.019_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/09273948.2015.1099680","article-title":"Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment","volume":"25","author":"Deuter","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2018.12.019_bib22","first-page":"1","article-title":"Efficacy of anti-IL6-receptor tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review","author":"Calvo-R\u00edo","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.ajo.2018.12.019_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"10.1016\/j.ajo.2018.12.019_bib24","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","article-title":"Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema","volume":"38","author":"Mesquida","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2018.12.019_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (month-6) outcomes of the STOP-Uveitis Study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"4 Suppl 84","key":"10.1016\/j.ajo.2018.12.019_bib26","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"6 Suppl 102","key":"10.1016\/j.ajo.2018.12.019_bib27","first-page":"S34","article-title":"The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: results of a multicentre open-label study","volume":"34","author":"Santos-G\u00f3mez","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2018.12.019_bib28","first-page":"864","article-title":"Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.ajo.2018.12.019_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ajo.2018.12.019_bib30","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: a 1-year follow-up study of 124 patients","volume":"53","author":"Calvo-R\u00edo","year":"2014","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.ajo.2018.12.019_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2018.12.019_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2018.12.019_bib33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/eye.2016.115","article-title":"Uveitic macular edema","volume":"30","author":"Fardeau","year":"2016","journal-title":"Eye"},{"issue":"7","key":"10.1016\/j.ajo.2018.12.019_bib34","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1586\/1744666X.2016.1166052","article-title":"Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis","volume":"12","author":"Maleki","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ajo.2018.12.019_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/JIR.S5706","article-title":"Etiology and treatment of the inflammatory causes of cystoid macular edema","volume":"2","author":"Cho","year":"2009","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.ajo.2018.12.019_bib36","doi-asserted-by":"crossref","first-page":"946048","DOI":"10.1155\/2012\/946048","article-title":"Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions","volume":"2012","author":"Ogata","year":"2012","journal-title":"Int J Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2018.12.019_bib37","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"3 Suppl 97","key":"10.1016\/j.ajo.2018.12.019_bib38","first-page":"S44","article-title":"Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review","volume":"34","author":"Loricera","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2018.12.019_bib39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","article-title":"Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients","volume":"44","author":"Loricera","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"3 Suppl 82","key":"10.1016\/j.ajo.2018.12.019_bib40","first-page":"S79","article-title":"Tocilizumab in refractory aortitis: study on 16 patients and literature review","volume":"32","author":"Loricera","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ajo.2018.12.019_bib41","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2147\/OPTH.S68595","article-title":"Targeting interleukin-6 for noninfectious uveitis","volume":"9","author":"Lin","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2018.12.019_bib42","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s00417-012-2243-x","article-title":"Tocilizumab treatment for recalcitrant uveitic macular edema","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2018.12.019_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00417-013-2466-5","article-title":"Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report","volume":"252","author":"Ad\u00e1n","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4 Suppl 84","key":"10.1016\/j.ajo.2018.12.019_bib44","first-page":"S75","article-title":"Tocilizumab in severe and refractory non-infectious uveitis","volume":"32","author":"Papo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.ajo.2018.12.019_bib45","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3899\/jrheum.160231","article-title":"Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis","volume":"43","author":"Tappeiner","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2018.12.019_bib46","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Behcet\u2019s disease: four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ajo.2018.12.019_bib47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cei.12295","article-title":"Interleukin-6 blockade in ocular inflammatory diseases","volume":"176","author":"Mesquida","year":"2014","journal-title":"Clin Exp Immunol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419300030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419300030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:38:44Z","timestamp":1757597924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939419300030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":47,"alternative-id":["S0002939419300030"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2018.12.019","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2018.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}